Veru Receives FDA Clarity on Enobosarm-GLP-1 Combination for Obesity Treatment, Plans Phase 2b PLATEAU Study
核心洞察
Veru Inc. reported positive Phase 2b QUALITY study results showing enobosarm combined with semaglutide achieved 100% preservation of lean mass and 12% greater fat loss compared to semaglutide alone in older patients with obesity.
The FDA confirmed incremental weight loss as an acceptable primary endpoint for approval, with enobosarm 3 mg dose approved for future development in combination with GLP-1 receptor agonists.
The company plans to initiate the Phase 2b PLATEAU clinical study in Q1 2026, targeting patients aged 65 or older with BMI ≥35, with interim analysis results expected in Q1 2027.
Veru Inc., a late-stage biopharmaceutical company, has received regulatory clarity from the FDA for its enobosarm obesity program and announced plans to advance into Phase 2b trials following positive results from its QUALITY study. The company reported that enobosarm in combination with GLP-1 receptor agonists represents a potential next-generation approach to obesity treatment that preserves muscle mass while enhancing fat loss.
FDA Provides Regulatory Pathway for Combination Therapy
The FDA has confirmed that incremental weight loss is an acceptable primary endpoint for approval of enobosarm in combination with GLP-1 receptor agonists. According to the regulatory guidance received in September 2025, two potential pathways exist for approval: achieving at least 5% placebo-corrected weight loss difference at 52 weeks, or demonstrating clinically significant benefits such as preservation of physical function even with smaller weight loss differences.
"The current FDA regulatory guidance for muscle preservation drugs in combination with GLP-1 RA drugs in the treatment of obesity seems particularly well aligned for enobosarm," said Mitchell Steiner, M.D., Chairman, President, and CEO of Veru. The FDA has also confirmed that the 3 mg dose of enobosarm is acceptable for future clinical development.
Phase 2b QUALITY Study Demonstrates Efficacy
The completed Phase 2b QUALITY study evaluated enobosarm in combination with semaglutide in 168 older patients (≥60 years) over 16 weeks. The study met its primary endpoint, with the enobosarm 3 mg group achieving statistically significant 100% preservation of total lean mass compared to placebo plus semaglutide.
Key efficacy results included 12% greater fat loss in the enobosarm group compared to placebo, with the tissue composition of weight loss being 100% fat mass versus 66% fat mass and 34% lean mass in the control group. In a subset analysis of patients with baseline BMI ≥35, incremental weight loss was observed, with 65.4% of patients in the enobosarm group losing at least 5% of body weight compared to 47.4% in the semaglutide-only group.
The study also demonstrated preservation of physical function, with only 17.6% of enobosarm-treated patients experiencing a ≥10% decline in stair climb power compared to 44.8% in the control group, representing a 59.8% relative reduction in functional decline.
Addressing Weight Loss Plateau Challenge
Dr. Steiner highlighted a critical clinical challenge that the combination therapy aims to address: "An emerging, common, and serious clinical and therapeutic challenge with GLP-1 RA monotherapy is that 88% of patients with obesity after one year on drug hit a weight loss plateau where they stop losing additional weight while on a GLP-1 RA. Unfortunately, 62.6% of these patients still had clinical obesity at the time they reached the weight loss plateau based on the SURMOUNT-1 study."
The maintenance extension portion of the QUALITY study showed that after discontinuing semaglutide, patients receiving enobosarm monotherapy regained significantly less weight (46% reduction in weight regain) compared to placebo, with the regained weight being 100% lean mass rather than a mixture of fat and lean tissue.
Phase 2b PLATEAU Study Design
The planned Phase 2b PLATEAU clinical trial will enroll approximately 200 patients aged ≥65 with BMI ≥35 who are initiating GLP-1 receptor agonist treatment. The primary efficacy endpoint will be percent change from baseline in total body weight at 72 weeks, with an interim analysis at 36 weeks to assess changes in lean body mass and fat mass.
Key secondary endpoints will focus on physical function measures including stair climb test, mobility disability status, and patient-reported outcome questionnaires, as well as body composition endpoints including total fat mass, total lean mass, and bone mineral density.
"The Phase 2b PLATEAU clinical study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau in older patients with obesity receiving GLP-1 RA treatment with the expectation that patients will achieve clinically meaningful incremental weight reduction and preserve muscle mass and physical function at 52 weeks," the company stated.
Financial Position and Timeline
Veru reported a net loss from continuing operations of $15.7 million for fiscal year 2025, compared to $35.3 million in the previous year. Research and development expenses increased to $15.6 million from $12.8 million, while general and administrative expenses decreased to $19.9 million from $24.6 million.
The company completed a public offering post fiscal year-end, raising approximately $23.4 million in net proceeds to fund the upcoming PLATEAU study. The Phase 2b PLATEAU clinical study is expected to start in Q1 2026, with interim analysis results anticipated in Q1 2027.
Safety Profile
The QUALITY study demonstrated a positive safety profile for the enobosarm-semaglutide combination, with no additional gastrointestinal adverse events compared to semaglutide alone. During the maintenance extension phase with enobosarm monotherapy, there were essentially no GI side effects, no evidence of drug-induced liver injury, and no increases in obstructive sleep apnea. No adverse events related to masculinization in women or increases in prostate-specific antigen in men were observed.